Role of galectin-3 in obesity and impaired glucose homeostasis

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Menini, Stefano ^a   Iacobini, Carla ^a   Blasetti Fantauzzi, Claudia ^a   Pesce, Carlo M ^b   Pugliese, Giuseppe ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; MAMMALS; NUTRITION; PHYSIOLOGY;

ADAPTIVE IMMUNITY; ADIPOSE TISSUE; BIOLOGICAL FUNCTIONS; GLUCOSE HOMEOSTASIS; PROINFLAMMATORY; SYSTEMIC INFLAMMATION; THERAPEUTIC TARGETS; TYPE-2 DIABETES;

TISSUE HOMEOSTASIS;

GALECTIN 3; GLUCOSE;

ADIPOSE TISSUE; FAT MASS; GLUCOSE HOMEOSTASIS; HUMAN; INFLAMMATION; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; ANIMAL; CHEMISTRY; HOMEOSTASIS; METABOLISM; PATHOLOGY;

ADIPOSE TISSUE; ANIMALS; DIABETES MELLITUS, TYPE 2; GALECTIN 3; GLUCOSE; HOMEOSTASIS; HUMANS; OBESITY;

EID: 84953256996     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/9618092     Document Type: Review

References (52)

1. A. U. Newlaczyl and L.-G. Yu, Galectin-3-a jack-of-all-trades in cancer, Cancer Letters, vol. 313, no. 2, pp. 123-128, 2011.
2. J. Dumic, S. Dabelic, and M. Flogel, Galectin-3: an openended story, Biochimica et Biophysica Acta-General Subjects, vol. 1760, no. 4, pp. 616-635, 2006.
3. G. Pugliese, C. Iacobini, C. M. Pesce, and S. Menini, Galectin-3: an emerging all-out player in metabolic disorders and their complications, Glycobiology, vol. 25, no. 2, pp. 136-150, 2015.
4. G. Pugliese, C. Iacobini, C. Ricci, C. B. Fantauzzi, and S. Menini, Galectin-3 in diabetic patients, Clinical Chemistry and Laboratory Medicine, vol. 52, no. 10, pp. 1413-1423, 2014.
5. C. Iacobini, L. Amadio, G. Oddi et al., Role of galectin-3 in diabetic nephropathy, Journal of the American Society of Nephrology, vol. 14, supplement 3, pp. S264-S270, 2003.
6. G. Pugliese, Do advanced glycation end products contribute to the development of long-term diabetic complications? Nutrition, Metabolism and Cardiovascular Diseases, vol. 18, no. 7, pp. 457-460, 2008.
7. S. F. Yan, R. Ramasamy, and A. M. Schmidt, Mechanisms of Disease: advanced glycation end-products and their receptor in inflammation and diabetes complications, Nature Clinical Practice Endocrinology and Metabolism, vol. 4, no. 5, pp. 285-293, 2008.
8. S. H. Barondes, D. N. W. Cooper, M. A. Gitt, and H. Leffler, Galectins. Structure and function of a large family of animal lectins,The Journal of Biological Chemistry, vol. 269, no. 33, pp. 20807-20810, 1994.
9. F.-T. Liu, R. J. Patterson, and J. L. Wang, Intracellular functions of galectins, Biochimica et Biophysica Acta-General Subjects, vol. 1572, no. 2-3, pp. 263-273, 2002.
10. R. P. Menon and R. C. Hughes, Determinants in theN-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex, European Journal of Biochemistry, vol. 264, no. 2, pp. 569-576, 1999.
11. J. W. Dennis, I. R. Nabi, and M. Demetriou, Metabolism, cell surface organization, and disease, Cell, vol. 139, no. 7, pp. 1229-1241, 2009.
12. R. Lakshminarayan, C. Wunder, U. Becken et al., Galectin-3 drives glycosphingolipid-dependent biogenesis of clathrinindependent carriers, Nature cell Biology, vol. 16, no. 6, pp. 595-606, 2014.
13. E. A. Partridge, C. Le Roy, G. M. Di Guglielmo et al., Regulation of cytokine receptors by golgi N-glycan processing and endocytosis, Science, vol. 306, no. 5693, pp. 120-124, 2004.
14. S. F. Dagher, J. L. Wang, and R. J. Patterson, Identification of galectin-3 as a factor in pre-mRNA splicing, Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 4, pp. 1213-1217, 1995.
15. R.-Y. Yang, D. K. Hsu, and F.-T. Liu, Expression of galectin-3 modulates T-cell growth and apoptosis, Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 13, pp. 6737-6742, 1996.
16. T. Shimura, Y. Takenaka, T. Fukumori et al., Implication of galectin-3 inWnt signaling, Cancer Research, vol. 65, no. 9, pp. 3535-3537, 2005.
17. R. C. Hughes, Galectins as modulators of cell adhesion, Biochimie, vol. 83, no. 7, pp. 667-676, 2001.
18. T. Fukumori, Y. Takenaka, T. Yoshii et al., CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis, Cancer Research, vol. 63, no. 23, pp. 8302-8311, 2003.
19. R. Morgan, G. Gao, J. Pawling, J. W. Dennis, M. Demetriou, and B. Li, N-acetylglucosaminyltransferase V (Mgat5)-mediated N-glycosylation negatively regulates Th1 cytokine production by T cells, Journal of Immunology, vol. 173, no. 12, pp. 7200-7208, 2004.
20. M. Demetriou, M. Granovsky, S. Quaggin, and J. W. Dennis, Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation, Nature, vol. 409, no. 6821, pp. 733-739, 2001.
21. A. C. MacKinnon, S. L. Farnworth, P. S. Hodkinson et al., Regulation of alternative macrophage activation by galectin-3, Journal of Immunology, vol. 180, no. 4, pp. 2650-2658, 2008.
22. A. Karlsson, K. Christenson, M. Matlak et al., Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils, Glycobiology, vol. 19, no. 1, pp. 16-20, 2009.
23. G. E. Gonzalez, P. Cassaglia, S. Noli Truant et al., Galectin-3 is essential for early wound healing and ventricular remodeling after myocardial infarction in mice, International Journal of Cardiology, vol. 176, no. 3, pp. 1423-1425, 2014.
24. A. C. MacKinnon, M. A. Gibbons, S. L. Farnworth et al., Regulation of transforming growth factor-α1-driven lung fibrosis by galectin-3, American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 5, pp. 537-546, 2012.
25. N. C. Henderson, A. C. Mackinnon, S. L. Farnworth et al., Galectin-3 regulates myofibroblast activation and hepatic fibrosis, Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 13, pp. 5060-5065, 2006.
26. B. S. Mietto, S. Jurgensen, L. Alves et al., Lack of galectin-3 speeds Wallerian degeneration by altering TLR and proinflammatory cytokine expressions in injured sciatic nerve, European Journal of Neuroscience, vol. 37, no. 10, pp. 1682-1690, 2013.
27. Y. Li, M. Komai-Koma, D. S. Gilchrist et al., Galectin-3 is a negative regulator of lipopolysaccharide-mediated inflammation, Journal of Immunology, vol. 181, no. 4, pp. 2781-2789, 2008.
28. M. A. Burguillos, M. Svensson, T. Schulte et al., Microgliasecreted galectin-3 acts as a Toll-like receptor 4 ligand and contributes to microglial activation, Cell Reports, vol. 10, no. 9, pp. 1626-1638, 2015.
29. A. S. Daar, P. A. Singer, D. L. Persad et al., Grand challenges in chronic non-communicable diseases, Nature, vol. 450, no. 7169, pp. 494-496, 2007.
30. S. Kodama, C. Horikawa, K. Fujihara et al., Quantitative relationship between body weight gain in adulthood and incident type 2 diabetes: a meta-analysis, Obesity Reviews, vol. 15, no. 3, pp. 202-214, 2014.
31. S. E. Kahn, R. L. Hull, and K. M. Utzschneider, Mechanisms linking obesity to insulin resistance and type 2 diabetes, Nature, vol. 444, no. 7121, pp. 840-846, 2006.
32. A. M. Schmidt, The growing problem of obesity: mechanisms, consequences, and therapeutic approaches, Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 35, pp. e19-e23, 2015.
33. R. A. de Boer, D. J. van Veldhuisen, R. T. Gansevoort et al., The fibrosis marker galectin-3 and outcome in the general population, Journal of InternalMedicine, vol. 272, no. 1, pp. 55-64, 2012.
34. J. E. Ho, C. Liu, A. Lyass et al., Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community, Journal of the American College of Cardiology, vol. 60, no. 14, pp. 1249-1256, 2012.
35. J. Weigert, M. Neumeier, J. Wanninger et al., Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes, Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 3, pp. 1404-1411, 2010.
36. C. Iacobini, S. Menini, C. Ricci et al., Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver, Journal of Hepatology, vol. 54, no. 5, pp. 975-983, 2011.
37. H. Yilmaz, M. Cakmak, O. Inan, T. Darcin, and A. Akcay, Increased levels of galectin-3 were associated with prediabetes and diabetes: new risk factor? Journal of Endocrinological Investigation, vol. 38, no. 5, pp. 527-533, 2015.
38. E. S. Kang, Y. S. Yun, S. W. Park et al., Limitation of the validity of the homeostasis model assessment as an index of insulin resistance in Korea, Metabolism, vol. 54, no. 2, pp. 206-211, 2005.
39. T. Ohkura, Y. Fujioka, R. Nakanishi et al., Lowserumgalectin-3 concentrations are associated with insulin resistance in patients with type 2 diabetes mellitus, Diabetology and Metabolic Syndrome, vol. 6, no. 1, article 106, 2014.
40. F. Song and A. M. Schmidt, Glycation and insulin resistance: novelmechanisms and unique targets? Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 8, pp. 1760-1765, 2012.
41. N. N. Pejnovic, J. M. Pantic, I. P. Jovanovic et al., Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets, Diabetes, vol. 62, no. 6, pp. 1932-1944, 2013.
42. J. Pang, D. H. Rhodes, M. Pini et al., Increased adiposity, dysregulated glucosemetabolism and systemic inflammation in galectin-3 KO mice, PLoS ONE, vol. 8, no. 2, Article ID e57915, 2013.
43. S. Kooptiwut, M. Kebede, S. Zraika et al., High glucoseinduced impairment in insulin secretion is associated with reduction in islet glucokinase in amousemodel of susceptibility to islet dysfunction, Journal ofMolecular Endocrinology, vol. 35, no. 1, pp. 39-48, 2005.
44. F. Song, C. H. del Pozo, R. Rosario et al., RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice, Diabetes, vol. 63, no. 6, pp. 1948-1965, 2014.
45. A. E. Karlsen, Z. M. Storling, T. Sparre et al., Immune-mediated β-cell destruction in vitro and in vivo-a pivotal role for galectin-3, Biochemical and Biophysical Research Communications, vol. 344, no. 1, pp. 406-415, 2006.
46. E. P. K. Mensah-Brown, Z. Al Rabesi, A. Shahin et al., Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice, Clinical Immunology, vol. 130, no. 1, pp. 83-88, 2009.
47. J.-H. Baek, S.-J. Kim, H. G. Kang et al., Galectin-3 activates PPARγ and supports white adipose tissue formation and highfat diet-induced obesity, Endocrinology, vol. 156, no. 1, pp. 147-156, 2015.
48. K. Kiwaki, C. M. Novak, D. K. Hsu, F.-T. Liu, and J. A. Levine, Galectin-3 stimulates preadipocyte proliferation and is upregulated in growing adipose tissue, Obesity, vol. 15, no. 1, pp. 32-39, 2007.
49. S. Virtue and A. Vidal-Puig, Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome-an allostatic perspective, Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, vol. 1801, no. 3, pp. 338-349, 2010.
50. F. Badoud, M. Perreault, M. A. Zulyniak, and D. M. Mutch, Molecular insights into the role of white adipose tissue in metabolically unhealthy normal weight and metabolically healthy obese individuals, The FASEB Journal, vol. 29, no. 3, pp. 748-758, 2015.
51. D. L. Johannsen, Y. Tchoukalova, C. S. Tam et al., Effect of 8 weeks of overfeeding on ectopic fat deposition and insulin sensitivity: testing the adipose tissue expandability hypothesis, Diabetes Care, vol. 37, no. 10, pp. 2789-2797, 2014.
52. T. McLaughlin, A. Sherman, P. Tsao et al., Enhanced proportion of small adipose cells in insulin-resistant vs insulinsensitive obese individuals implicates impaired adipogenesis, Diabetologia, vol. 50, no. 8, pp. 1707-1715, 2007.